Form 4: Vaxcyte Director Olivier Brandicourt Receives Equity Grants

Vaxcyte, Inc. director Olivier Brandicourt was granted 1,357 restricted stock units and options to purchase 6,750 shares of common stock.

Summary

• Director Olivier Brandicourt of Vaxcyte, Inc. (PCVX) was granted equity compensation on January 15, 2026.
• The grants include 1,357 restricted stock units (RSUs) and options to purchase 6,750 shares of common stock.
• The RSUs represent a contingent right to receive one share of common stock each, with a transaction price of $0.
• The stock options have an exercise price of $48.04 per share and were granted at a price of $0.
• Both the RSUs and the shares underlying the options will vest fully on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, subject to acceleration and continuous service.
• Following these transactions, Olivier Brandicourt directly beneficially owns 2,505 shares of common stock and 6,750 stock options.

Sentiment

Score: 7

Explanation: The filing reports an equity grant to a director, which is a positive signal of continued alignment between management and shareholder interests. It's a routine compensation event, not indicative of extraordinary news, hence a moderately positive score.

Positives

• Director Olivier Brandicourt received equity compensation, aligning his interests with shareholders.
• The grants include 1,357 restricted stock units and options for 6,750 shares, indicating continued commitment to the director.

Future Outlook

The vesting schedules for the granted restricted stock units and stock options extend to June 12, 2026, or the day prior to the next annual meeting of stockholders, indicating a future commitment period for the director's service.

Industry Context

This equity grant to a director is a standard practice in the biotechnology and pharmaceutical industry for executive and board compensation, aiming to align leadership incentives with long-term shareholder value creation. It reflects ongoing efforts to retain and motivate key personnel in a competitive talent landscape.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to a director is a common compensation structure in the biotech sector, comparable to practices at companies like Moderna, BioNTech, or Pfizer, which frequently use equity-based incentives to attract and retain top talent.
• The vesting schedule tied to continued service and future dates is also standard for such grants, ensuring long-term alignment.

Related Party Transactions

• Director Olivier Brandicourt, a related party, received 1,357 restricted stock units and options to purchase 6,750 shares of common stock as compensation.

Stakeholder Impact

• Shareholders: The equity grants align the director's financial interests with long-term shareholder value.
• Employees: Standard equity compensation practices can positively influence employee morale and retention by demonstrating a commitment to performance-based incentives.
• Management: The grants serve as an incentive for the director's continued service and performance.

Next Steps

• The restricted stock units and stock options will vest monthly, with full vesting on the earlier of June 12, 2026, or the day prior to the next annual meeting of stockholders, contingent on continuous service.

Key Dates

Recommendation

This Form 4 filing details a routine equity compensation grant to a director and does not contain information that would fundamentally alter the investment thesis for Vaxcyte, Inc. While insider ownership alignment is generally positive, this specific transaction is an expected part of director compensation and does not warrant a change in investment recommendation based solely on this filing.

Keywords

Vaxcyte, PCVX, Olivier Brandicourt, Form 4, SEC Filing, Insider Trading, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation